Scale with Non Dilutive Funding and Keep Your Equity
You’ve built something customers want. The roadmap is real, the next milestone has a date, and the team can execute. What you don’t want is to sell another percentage point just to cover hiring, parts, or supplier deposits.
Non dilutive funding is capital you can use to scale without giving up equity, typically grants, R&D tax credit advances, innovation loans, and revenue‑based facilities. If the roadmap slips, acquisition costs compound and the next round gets harder; the right non‑dilutive facility prevents that slide.
This guide shows how to finance the next 90–180 days with UK options: grants and grant advances, R&D tax credit advances, revenue‑based facilities, and Innovate UK innovation loans. We explain fit, sizing, and what to prepare so underwriting is quick. This guide to non dilutive funding covers the UK options founders use.
SPRK Capital is institutionally backed, including a £20 million facility with British Business Investments, which gives us the capacity and reliability high‑growth teams expect when timing matters. If you’re actively exploring non dilutive funding to hit your next milestone, you’re in the right place.
What problem are you solving right now?
Strong funding decisions start with a single sentence you can defend in front of your board. Are you bridging a timing gap while you wait for HMRC or a grant payment? Are you scaling what already converts, such as new hires, parts, and go‑to‑market, without slowing the roadmap? Or are you buying time to reach a stronger valuation before the next equity round? When we advise teams, we won’t discuss products until that job is clear. Once it is, the instrument usually picks itself.
Here’s how the main options map to real situations, with the operational context we look for when we underwrite.
Are grants (and grant advances) right for milestone‑driven projects?
Grants work when your programme has clear scope, milestones, and defrayal rules. As a form of non dilutive funding, a grant advance brings cash forward, so suppliers start on time. Most issues are timing, not eligibility.
Do it well:
- Lock milestones and evidence before you draw.
- Reconcile invoices and bank statements without manual fixes.
- Draw close to when you place POs to avoid drift.
Smart & Horizon: Innovate UK paused Smart Grants in Jan 2025 and is running targeted pilots; check call‑specific competitions. UK applicants remain eligible for Horizon Europe calls through association, with opportunities to 2027.
How this helps your business: you keep suppliers moving on milestone dates and cut the true cash cost of R&D.
R&D advance vs. Innovation Term Loan: an R&D advance funds against an expected claim; the SPRK Innovation Term Loan is a 36‑month facility sized up to 150% of your latest R&D tax credit, with fixed repayments that HMRC prepayments can reduce.
Prefer to talk it through? Contact the SPRK team for a quick sense‑check.
How do R&D tax credit advances work in practice?
With a well‑evidenced claim, an R&D advance turns future relief into working capital. This non dilutive funding route keeps hiring and POs on schedule while HMRC processes the claim. From April 2024, claims sit under the merged RDEC scheme with a 20% expenditure credit. If you are loss‑making and R&D‑intensive (≥30%), ERIS can increase the net benefit (with a grace period if you met the threshold in the previous year). Keep the PAYE/NIC cap in mind (£20,000 + 3× relevant PAYE/NIC).
Size it safely: model base/high/low outcomes and anchor to the low case; confirm PAYE/NIC headroom; keep the AIF tight (uncertainty, advance over baseline, mapping from costs to activities).
How this helps your business: you convert a defensible claim into cash now, so delivery stays on track.
Is revenue‑based financing a fit for our cash cycle?
RBF suits predictable revenue and healthy margins. It is another non dilutive funding option for teams with repeatable sales. Repay a % of monthly revenue until a fixed total is reached. Underwrite to your trough month and compare on all‑in cost to maturity.
When it works: use it for paid acquisition with payback inside term, short cash conversion inventory, and repeatable channel spend.
When not to use it: if payback sits beyond the term or margins are thin, RBF strains cash flow.
Example: Facility £250k × 5% of revenue; trough month £300k ⇒ worst‑case repayment £15k.
How this helps your business: fund near‑term payback while protecting working capital in slower months.
When should we choose an Innovate UK innovation loan?
Choose an innovation loan for late‑stage R&D with a route to customers. This non dilutive funding option supports larger programmes over multiple years. Rates and terms vary by competition; UKRI examples show fixed rates (e.g., 7.4% p.a.) with part payable and part deferred interest during the project phase, then repayments later. When HMRC pays your R&D credit, you can apply that prepayment to reduce remaining instalments on the 36‑month SPRK Innovation Term Loan.
Plan for decision timelines and run a parallel path by lining up a grant or an R&D advance so work keeps moving. Sequence the instruments to reduce timing risk without dilution.
When not to use it: If you can’t evidence late‑stage development with a route to customers, apply later or use shorter‑term facilities first.
How this helps your business: you fund late‑stage development on a multi‑year schedule and lower monthly outflows when HMRC prepayments arrive.
Two quick scenarios
SaaS (MRR ~£150k): Use a compact RBF line for paid channels and an R&D advance for 2–3 months of product salaries to hold release dates.
Hardware/Deep Tech: Fund late‑stage development with an innovation loan and draw grant advances at milestone windows; use an R&D advance if lead times slip.
With the options on the table, choose based on speed, total cost to maturity, friction, and control. Here’s how that plays out.
Which non dilutive funding option should I choose?
Quick chooser:
- Pick a grant advance if your work is milestone‑based and you need suppliers moving before reimbursement.
- Pick an R&D advance if your evidence is complete and you’re bridging to HMRC payment while keeping the build on schedule.
- Pick RBF if payback is inside the facility term and revenue is predictable enough to underwrite to the trough month.
- Pick the SPRK Innovation Term Loan when you want multi‑year predictability sized to your latest R&D claim (with instalments that can fall as HMRC pays).
Want details on our 36‑month Innovation Term Loan? See our non dilutive funding page.
Still between options? Share your milestone and latest R&D claim; we’ll price an R&D advance and a 36‑month Innovation Term Loan side by side so you can pick the cleanest path.
What will a lender ask for to move fast?
For non dilutive funding decisions, bring a clean pack so we can move quickly:
- Management accounts and a 12‑month forecast
- 3–6 months of bank statements and AR/AP ageing
- R&D pack (AIF, narratives, cost summaries, apportionment, PAYE/NIC)
- Relevant grant letters and milestone schedules
Add months of runway without selling a share
We size to your low case and show the impact on cash in the next 90 days. If you want non dilutive funding that preserves ownership and momentum, follow the steps below.
Here is the fastest route:
- Share four numbers: your latest R&D tax credit estimate, cash at bank, average monthly net burn, and any overdue PAYE/NIC. If you’re exploring the Innovation Term Loan, include your latest filed R&D claim.
- Flag constraints: tell us about any existing charges or debentures so we can size and structure correctly.
- Upload evidence: your AIF (if drafted) or a claim‑pack summary, plus grant award letters and milestone schedules if you plan to combine products.
- Pick the product: we will price an R&D advance and a 36‑month Innovation Term Loan side by side so you can choose the cleanest non‑dilutive path.
If you prefer a quick sense‑check first, send these details by reply and we’ll confirm fit before paperwork.
